1. Introduction {#sec0005}
===============

A novel human coronavirus, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was identified in Wuhan, China, in late 2019 ([@bib0075]). Within few weeks, outbreaks of so-called 2019 novel coronavirus (nCoV) infection had spread worldwide. On February 11, 2020, the World Health Organization announced coronavirus disease 2019 (COVID-19) as the name of this new disease, and exactly one month later, declared the situation a pandemic \[2--10\]. As of April 2020, the pandemic is ongoing in the majority of countries \[1, 11\]. Data from China suggest that 40 % of patients who require intensive care unit (ICU) admission share similar comorbidities, such as diabetes and preexisting heart disease ([@bib0125]).

Although an extensive literature is available to guide management of the acute respiratory distress syndrome (ARDS), COVID-19 is a new viral infection of the lower respiratory tract whose pathophysiology and treatment are still poorly understood. More than 80 % of confirmed COVID-19 cases present as a mild febrile illness. However, a small proportion of patients will experience critical illness, with many of these requiring mechanical ventilation ([@bib0025]). In one study conducted in Wuhan, 41.8 % of patients hospitalized for COVID-19 develop acute respiratory failure, with a fatality rate of 52.4 % ([@bib0130]). The median time from symptom onset to respiratory failure was 8 days ([@bib0125]). At ICU admission, most COVID-19 patients present acute onset of hypoxemic respiratory failure, with oxygen saturation (SpO~2~) levels below 93 % ([@bib0145]). Risk factors associated with respiratory failure and death include older age, neutrophilia, coagulation dysfunction, organ failure, and elevated D-dimer ([@bib0130]). At autopsy, the lungs of patients with confirmed SARS-CoV-19 infection exhibit slurry within the alveolar cavity, fibrinous exudation, and proliferation of Type II alveolar epithelial cells and macrophages. Moreover, alveolar septal vascular congestion, edema, vascular thrombi with focal intraparenchymal hemorrhage, and hemorrhagic infarction are common, suggesting an important role of the vascular compartment and lung perfusion in the pathophysiology of COVID-19 ([@bib0140]).

To date, the respiratory management of COVID-19 has relied on the general principles of ARDS management; however, computed tomography of the chest may provide interesting insights into the pathophysiology and individualization of mechanical ventilation in these patients. The aim of this manuscript is to provide brief guidance for respiratory management before, during, and after mechanical ventilation in COVID-19 patients, based on the literature and our direct experience with this population. Furthermore, we describe three distinct phenotypes of COVID-19 pneumonia, represented by distinct patterns of chest CT findings, their pathophysiological correlations, and their implications for management.

1.1. Chest CT findings in COVID-19 {#sec0010}
----------------------------------

Computed tomography (CT) of the chest is essential to understand the diversity of pathological findings and optimize and individualize therapy for COVID-19 patients ([Fig. 1](#fig0005){ref-type="fig"} ) \[18--22\].Fig. 1Summary of the key points for respiratory management of COVID-19 patients according to the three distinct phenotypes.Phenotype 1: good compliance, but severe hypoxemia. PEEP should be set with the aim to redistribute pulmonary flow and reduce shunting. In this case, using the principles generally applied in ARDS, and thus setting the PEEP according to the best driving pressure, will probably lead to use of lower PEEP (as the compliance is good), resulting in less oxygenation. iNO could be considered in these cases, and prone positioning can redistribute perfusion, but is generally not very useful at this stage.Phenotype 2: atelectasis and derecruitment are predominant. In this case, high PEEP and prone positioning can recruit non-aerated areas of the lung. Recruitment maneuvers (RMs) may play a role in these cases, whereas iNO is less useful.Phenotype 3: typical CT pattern of moderate-to-severe ARDS, with alveolar edema and low compliance. Respiratory settings should follow the general principles applied for ARDS. PEEP should be set according to the best driving pressure; eventually, RMs, prone positioning, and ECMO may be considered.Fig. 1

Typical chest CT findings in COVID-19 include bilateral infiltrates with multiple ground-glass opacities or consolidation, but no edema ([@bib0145]). Some patients exhibit asymmetrical edematous lesions and atelectasis, or scattered fibrosis ([@bib0145]). Given the low resolution of plain radiography, we recommend that chest CT be performed in all severe patients. However, unfortunately, CT scanning is not available in all emergency departments, and may require transfer of the patient to a radiology suite. Lung ultrasound is a developing technique which has been used extensively in ARDS patients over the last decades ([@bib0095]) and may be useful for safe, noninvasive bedside diagnosis of COVID-19 pneumonia; specific lung ultrasound patterns have been described ([@bib0095]). Nevertheless, this technique has several limitations, such as the need for formal training, interobserver variability, and limited accuracy (particularly in obese patients and in the presence of subcutaneous emphysema).

To date, there have been few reports of chest CT findings in COVID-19 \[17--21\]. CT imaging demonstrates five stages according to the time since onset and disease progression: 1) Very early stage (asymptomatic, positive nasopharyngeal swab): single, double, or scattered focal ground-glass opacity, nodules located in central lobule surrounded by patchy ground-glass opacities, patchy consolidation and air bronchogram sign; 2) Early phase: (1--3 days after clinical manifestations): dilatation and congestion of alveolar septal capillaries, exudation of fluid in alveolar cavity, interlobular interstitial edema; 3) Rapid progression phase (3--7 days after clinical manifestations): massive accumulation of cell-rich exudates in the alveolar cavity, vascular expansion and exudation in the interstitium, large-scale light consolidation with air bronchogram sign; 4) Consolidation stage (7--14 days after clinical manifestations): fibrous exudation of the alveolar cavity with multiple patchy consolidations; and 5) Dissipation stage (2--3 weeks after clinical manifestations): grid-like thickening of interlobular septum, thickening and strip-like twisting of bronchial walls, and a few scattered patchy consolidations.

Monitoring of chest CT features is of extreme importance in these patients to personalize treatment strategies and mechanical ventilator settings ([Fig. 1](#fig0005){ref-type="fig"}). In particular, chest CT scan can help in the assessment of areas of atelectasis or overperfusion and shunting, as well as evaluation of the risk of pulmonary embolism. We have identified three main chest CT patterns in COVID-19 patients, representing three different phenotypes: 1) multiple, focal, possibly overperfused ground-glass opacities mainly in the subpleural region; 2) inhomogeneously distributed atelectasis and peribronchial opacities; and 3) a patchy ARDS-like pattern. These differing phenotypes are attributable to different pathophysiological mechanisms, and therefore require different ventilatory strategies; however, the phenotypes we propose seem to be in agreement with Gattinoni et al.([@bib0055];[@bib0060]), who proposed a phenotype L (low elastance, low ventilation to perfusion ratio, and low lung reclutability) compatible with our phenotype 1, a phenotype H (high elastance, and simil ARDS pattern), compatible with our phenotype 3, and a transitioning phenotype, which reflects the evolution of the disease.

1.2. Oxygen therapy and noninvasive ventilation {#sec0015}
-----------------------------------------------

Supplemental oxygen is recommended in COVID-19 patients if the peripheral saturation of oxygen (SpO~2~) is below 93 %, and SpO~2~ should be maintained no higher than 96 % ([@bib0010]). Few data are available on the efficacy of noninvasive support---which includes continuous positive airway pressure (CPAP), noninvasive ventilation (NIV), and high flow nasal oxygen (HFNO)---in COVID-19 pneumonia. In patients with influenza A(H1N1) infection, noninvasive positive-pressure ventilation was associated with a high incidence of failure (57--85 %), and patients who failed noninvasive support experienced a higher mortality rate than those treated with early mechanical ventilation ([@bib0085])24\]. The experience in COVID-19 patients from Wuhan was similar, with a high rate of noninvasive support failure and need for intubation and mechanical ventilation in 76 % of cases; nevertheless, there was no difference in mortality between patients receiving noninvasive vs invasive ventilation ([@bib0135]). In general, noninvasive ventilatory management carries a high risk of generating negative (and unmeasured) intrathoracic pressures, and is thus potentially counterproductive ([@bib0020]). Noninvasive support also presents a higher risk of viral spread through mask leaks, with increased risk of transmission ([Fig. 2](#fig0010){ref-type="fig"} ). Furthermore, delayed intubation increases the risk of clinical deterioration and the need for emergency airway management. In general ICU patients, HFNO has been shown to decrease the need for tracheal intubation in acute hypoxemic respiratory failure when compared to conventional oxygen therapy, without impacting mortality ([@bib0105]). A randomized controlled trial comparing NIV and HFNO in patients with hypoxic respiratory failure showed that HFNO was able to reduce mortality at 90 days without affecting the need for intubation (50 % vs 47 %, p = 0.18) ([@bib0045]), while a meta-analysis comparing HFNO vs NIV demonstrated that HFNO is able to significantly decrease the need for intubation ([@bib0090]). Therefore, in adults with COVID-19 and acute respiratory failure, HFNO should be preferred over NIV. Both NIV and HFNO are being used extensively in COVID-19 patients, especially in cases of milder disease or to buy time before invasive ventilation is commenced. However, the potential advantages of using NIV or HFNO in these circumstances have to be balanced against their risks. When a patient presents with severe respiratory failure or on a downward spiral that suggests intubation will be inevitable, noninvasive respiratory support should not be attempted \[22\].Fig. 2Key points summarizing our recommendations for the respiratory management of COVID-19 patients.Fig. 2

1.3. Airway management and tracheal intubation {#sec0020}
----------------------------------------------

When hypoxemia and respiratory failure persist or worsen after oxygen therapy or within a short time (1 h) of placement of HFNO or NIV support, or in case of persistent hypercapnia, organ failure, coma, risk or aspiration, or hemodynamic instability, invasive mechanical ventilation should be implemented as soon as possible ([Fig. 2](#fig0010){ref-type="fig"}) ([@bib0080]). Hypoxemic respiratory failure and need for invasive ventilation should be considered when patients receiving standard oxygen therapy exhibit tachypnea (\> 30 bpm) and hypoxemia (SpO~2~ \< 90 % or partial pressure of oxygen (PaO~2~) \< 60 mmHg) with oxygen administered via a facemask and reservoir bag (gas flow of 10∼15 L/min, fraction of inspired oxygen (FiO~2~) 0.60--0.95). Similarly, when a patient under HFNO support with FiO~2~ \>70 % and gas flow \>50 L/min or NIV experiences persistent respiratory failure or deteriorates acutely, mechanical ventilation should be promptly initiated ([@bib0080]). [Fig. 3](#fig0015){ref-type="fig"} presents our algorithm for trialing CPAP and indications for centralization and intubation of patients with COVID-19 respiratory failure. According to our experience, phenotype 1 is likely to be found when patients are promptly intubated and receive only brief or no noninvasive respiratory support. Patients who receive prolonged noninvasive ventilation are likely to develop phenotype 2 or 3, thus becoming more difficult to ventilate, with lower compliance and worse deterioration of oxygenation.Fig. 3Genoa algorithm for the advanced respiratory management of patients with COVID-19-related respiratory failure. This algorithm establishes objective tests which can be performed at bedside to determine whether a patient can be managed on oxygen alone, thus rationalizing ventilator and PPE use, and provides clear steps for escalation to CPAP and intubation.Fig. 3

The process of endotracheal intubation is considered to pose a high risk of aerosol-based transmission \[30, 31\]. Some hospitals have created dedicated spaces for planned airway management of COVID-19 patients (such as airborne infection isolation rooms); negative pressure ventilation rooms with an antechamber are ideal to minimize exposure during the procedure, whereas positive-pressure areas must be avoided ([@bib0150]).

The intubation team should start the maneuver only after appropriate airborne/droplet protections are in place and all team members are wearing adequate personal protective equipment (PPE). Airway devices, venous access devices, anesthetics, suction, ventilators, and basic monitoring should be guaranteed and readily available before starting. A rapid difficult-airway assessment should be done to recognize those at risk for difficult airway management. Intubation should be performed by the most experienced clinician, with the help of another doctor, and the most familiar airway device should be the first choice for intubating ([@bib0150]). Preoxygenation with 100 % FiO~2~ for 5 min before induction of anesthesia could be useful. Pre-oxygenation should be performed, using a well-fitting occlusive face mask attached to a manual ventilation device with an oxygen source ([@bib0150]). A viral filter must be inserted between the facemask and manual ventilation device to minimize aerosolization. The viral filter should be applied directly to the face mask, since the greater the number of connections between the facemask and filter, the greater the risk of disconnection on the patient side and subsequent aerosolization of the virus ([@bib0150]).

Rapid sequence induction should be used as the default technique, unless concerns with airway difficulty make this inappropriate. The literature suggests administration of rocuronium (\>1.5 mg/kg ideal body weight) or suxamethonium (1.5 mg/kg total body weight) to obtain rapid onset of deep neuromuscular blockade and minimize the risk of the coughing during airway instrumentation \[31\]. Routine use of a videolaryngoscope is recommended for the first attempt at intubation to maximize the distance between the airway operator's face and the patient. The choice of videolaryngoscope should be made according to the skillset and clinical judgement of the airway operator ([@bib0015]). In case of failed intubation, a second-generation laryngeal mask should be placed to guarantee tracheal intubation passage through the mask with the aid of a fiberscope ([@bib0150]).

After intubation, if using a humidified ventilator circuit, the viral filter used for intubation will need to be removed promptly; if a dry circuit is used, a combined heat-moisture exchanger (HME) and viral filter can be left in place, but this means that nebulization cannot be administered without breaking the circuit (to place a nebulizer between the patient and the HME). If the viral filter has been removed, the ventilator should be placed on standby for all circuit disconnections. Each disconnection from the ventilator should occur with the tube clamped to minimize the risk of aerosolization.

1.4. Ventilatory strategies {#sec0025}
---------------------------

The cornerstone of management in respiratory failure is mechanical ventilation, always with the aim of minimizing ventilator-induced lung injury (VILI) ([@bib0040]). Early in the outbreak, all patients with severe COVID-19 were considered to have ARDS and consequently ventilated with low tidal volumes---6 mL/kg of predicted body weight (PBW)---and plateau pressure, as well as high positive end-expiratory pressure (PEEP) ([@bib0035]). The Surviving Sepsis Campaign Guidelines on the Management of Critically Ill Adults with [@bib0030] ([@bib0010]) recommend using low-tidal volume (V~T~) ventilation (V~T~ 4−8 mL/kg of PBW) instead of higher tidal volumes (V~T~ \>8 mL/kg PBW). Additionally, a higher PEEP (\>10 cm H~2~O) strategy should be preferred over a lower PEEP, and PEEP should be titrated according to FiO~2~ to maintain an appropriate SpO~2~ in order to reduce atelectasis and alveolar hyperinflation as well as pulmonary vascular resistance \[23\]. Even though COVID-19 patients fulfill the Berlin criteria for ARDS ([@bib0115]), the clinical and chest CT features of mechanically ventilated COVID-19 patients do not always resemble ARDS. In fact, these patients may present with relatively well-maintained lung mechanics (good compliance) but severe hypoxemia, which could be consequent to impaired lung perfusion. Moreover, chest CT patterns differ among patients and over time. As noted above, we have found that chest CT findings in COVID-19 fall into three different phenotypes, each warranting unique mechanical ventilation settings and management strategies, which should thus be individualized based on clinical and CT features ([Fig. 1](#fig0005){ref-type="fig"}, Additional File 1, Fig. S1).

In phenotype 1, lung compliance is preserved or even elevated; chest CT shows no or few alveolar areas to recruit, but rather high-perfusion areas ([Fig. 1](#fig0005){ref-type="fig"}, Additional File 1, Fig. S1A). In these cases, the main cause of hypoxemia seems to be not atelectasis, but impaired distribution of lung perfusion and shunting. Moderate PEEP levels may therefore be able to redistribute pulmonary blood flow from damaged to non-damaged lung areas; however, higher PEEP levels can impair cardiac function, thus increasing the need for fluids and vasoconstrictor drugs without having important effects on oxygenation. Tidal volumes \>6 mL/kg should also be considered.

In phenotype 2, atelectasis is inhomogenously distributed. Moderate to high PEEP can be therefore useful to improve lung recruitment, as well as lateral or prone positioning ([Fig. 1](#fig0005){ref-type="fig"}, Additional File 1, Fig. S1B).

In phenotype 3, general principles applied to ARDS management should be used, including low tidal volume (\<6 mL/kg) and PEEP titration according to PEEP/FiO2 table and respiratory mechanics \[32, 33\] ([Fig. 1](#fig0005){ref-type="fig"}, Additional File 1, Fig. S1C).

1.5. Rescue therapies {#sec0030}
---------------------

Prone positioning can have an important role in severe ARDS to redistribute pulmonary blood flow, reduce atelectasis, and improve oxygenation ([Fig. 2](#fig0010){ref-type="fig"}) ([@bib0065]). In a meta-analysis including more than 2000 patients with moderate to severe ARDS, prone ventilation for at least 12 h had a beneficial effect on mortality (five randomized controlled trials; relative risk 0.74, 95 % confidence interval 0.56 to 0.99); however, no effect on mortality was detected when prone ventilation was used for less than 12 h ([@bib0110]). A recent study showed that prone ventilation has been frequently used in COVID-19 patients (11.5 %) ([@bib0135]). However, based on the foregoing, we do *not* recommend prone positioning of COVID-19 patients with phenotype 1. It should be reserved for phenotypes 2 and 3, to redistribute pulmonary blood flow and reduce atelectasis.

In short, the recommendation to use prone positioning is associated with chest CT features and should be individualized and reevaluated in each patient over time. It is fundamental that a protocol for prone positioning by available and that proning be performed by specifically trained personnel to avoid risks of infection or accidental endotracheal tube disconnection from the ventilator ([@bib0010]).

Inhaled nitric oxide (iNO) can theoretically have an important role as rescue therapy to improve lung perfusion, but the effect of iNO is balanced by the lung anatomical pattern as well as by regional perfusion. Recently published guidelines ([@bib0010]) did not recommend routine use of iNO in COVID-19 patients with respiratory failure. In phenotype 1, iNO may potentially improve oxygenation by acting on lung perfusion ([Fig. 4](#fig0020){ref-type="fig"} **)**, but no data are available from this population.Fig. 4Individualized strategies and pathophysiological features according to chest CT findings.Fig. 4

Continuous infusion of neuromuscular blocking agents (NMBA) should be reserved for COVID-19 patients in which intermittent dosing may not suffice, such as: patients undergoing prone positioning, persistent ventilator asynchrony, and those with high plateau pressures ([@bib0005]).

Recruitment maneuvers (RMs) are not routinely recommended in COVID-19 patients \[43, 44\]. In a systematic review and meta-analysis including 1423 patients, traditional RMs significantly reduced mortality, whereas incremental PEEP titration RMs increased death rate. Patients with phenotype 1 are likely not to benefit from RMs, whereas in phenotype 2 and 3 RMs may help improve oxygenation. When needed, traditional RMs along with higher levels of PEEP should be preferred over incremental PEEP-based RMs ([@bib0050]).

Finally, in mechanically ventilated COVID-19 patients with refractory hypoxemia despite conventional treatment and prone positioning, veno-venous (VV) extracorporeal membrane oxygenation (ECMO) can be considered as an option. However, given the need for resources, training, and associated risks, it should be used as rescue therapy only, in carefully selected patients.

1.6. Hypercoagulability {#sec0035}
-----------------------

Patients with COVID-19 often present in a hypercoagulable state. Thromboembolic events, ranging from microemboli to massive pulmonary embolism, are common and can contribute to respiratory failure, as well as precipitate clinical deterioration (Additional File 2, Fig. S2). In a preprint study \[48\], decreased platelet counts, increased fibrinogen and [d]{.smallcaps}-dimer levels were observed in 1 out of 5 patients, and prolonged prothrombin time was detected in 62.1 %. In this context, early coagulation screening, serial echocardiography, and CT pulmonary angiography can provide important information, particularly in more severe cases with sudden respiratory or hemodynamic deterioration. In a recent retrospective study of 165 patients with COVID-19 \[49\], [d]{.smallcaps}-dimer and fibrinogen correlated linearly with CT imaging score and changed dynamically according to disease progression. Therefore, although the literature is lacking on this specific topic, strict monitoring and early anticoagulation should be considered to mitigate multiorgan damage in severe COVID-19.

1.7. Hemodynamic management {#sec0040}
---------------------------

Changes in pleural pressure (Ppl) and transpulmonary pressure can be detrimental to hemodynamics. The increase of Ppl after application of positive airway pressure has the effect of decreasing left ventricular afterload and blood pressure. Of note, if Ppl exceeds pulmonary venous pressure, West zone 2 conditions arise due to microvascular collapse; likewise, if Ppl and interstitial pressures overcome pulmonary arterial pressure, pulmonary blood flow is obstructed (West zone 1). In both conditions, alveolar pressure represents the driver that boosts right ventricle afterload ([@bib0120]).

During controlled mechanical ventilation, PEEP and tidal forces increase pulmonary vascular resistance and Ppl, thus influencing mean alveolar pressure (which can be clinically approximated to mean airway pressure). It can also be influenced by longer duty cycles and higher driving pressures ([@bib0120]). High mean arterial pressure can increase West zone 2 conditions, thus increasing dead space and shunt fraction. In some cases, elevated right-side pressures may overdistend the right ventricle, thus causing stiffness of the left ventricle in an interdependent manner. Such condition needs to be evaluated by changes in venous saturation of oxygen (SvO~2~), and arterial saturation (SaO~2~) ([@bib0120]).

1.8. Cardiac injury {#sec0045}
-------------------

Cardiac injury is common after COVID-19, occurring in 20--30 % of cases. It is heralded by increased levels of troponin and NT-proBNP, and is associated with poor outcome ([@bib0070]). Patients with a history of cardiovascular conditions, such as hypertension or diabetes, are at higher risk. We suggest close monitoring of cardiac function and serial echocardiography in all patients with COVID-19.

1.9. Sepsis {#sec0050}
-----------

Although in most cases COVID-19 patients present with isolated viral pneumonia, septic shock may occur and should be promptly recognized and treated. If fluids are needed, isosmotic crystalloids are preferred vs colloids; albumin may be considered as a resuscitation fluid; conservative fluid management should be adopted, and vasopressors should be administered if necessary to improve microcirculation, titrated to a target mean arterial pressure of 65 mmHg with lactate ≥2 mmol/L. Empiric antibiotics targeting any suspected potential bacterial superinfection should be administered as soon as possible. Systemic corticosteroids are controversial in severe ARDS; methylprednisolone can be used as appropriate for patients with rapid disease progression or severe illness. According to severity, 40--80 mg of methylprednisolone per day can be considered, and the total daily dose should not exceed 2 mg/kg. In a recent study ([@bib0130]), methylprednisolone therapy decreased the risk of death in COVID-19 patients with respiratory failure. However, due to lack of evidence, the routine use of corticosteroids should be avoided. Short courses (3--5 days) can be considered according to clinical status and chest imaging \[23\]. Corticosteroids might be especially useful in patients with a heightened inflammatory response; therefore, PCR and interleukin (IL)-6 levels should be considered when deciding whether to start steroids in these patients.

1.10. Weaning and extubation {#sec0055}
----------------------------

The weaning process should follow the general criteria for weaning in any type of respiratory failure. As specific criteria for extubation of COVID-19 patients have not yet been established, generic guidelines ([@bib0100]) should be followed. [Fig. 5](#fig0025){ref-type="fig"} presents our algorithm for weaning and extubation. Patients can be eligible for a trial of extubation once they are well awake, exhibit good cough reflexes, and have stable hemodynamic and ventilatory parameters. At this stage, a spontaneous breathing trial (SBT) is performed before considering endotracheal tube removal. NIV and HFNO can be considered after extubation ([@bib0080]). Patients should ideally be non-infective prior to extubation, but this is likely to be unfeasible. When patients are still at risk of transmission, few recommendations are available to reduce the risk of infection; these include placement of a simple oxygen mask on the patient immediately after extubation to minimize aerosolization, the use of high PEEP levels, and avoidance of cough. If feasible, separate beds should be reserved for patients suitable for extubation trials (regardless of whether they are still positive for SARS-CoV-2) to reduce the risk of reagudization and, ultimately, reinfection of other patients.Fig. 5Genoa algorithm for the weaning and extubation of patients with COVID-19.Fig. 5

2. Conclusions {#sec0060}
==============

The novel severe acute respiratory syndrome caused by SARS-CoV-2 progresses incredibly quickly and is associated with high fatality rates. Although the pulmonary pattern of critically ill patients with COVID-19 has been defined as ARDS, it does not always represent or even resemble ARDS. Chest CT scan features differ among patients, establishing distinct phenotypes; over time, these and might guide therapy and ventilator settings. Further studies are warranted to provide additional insight on the respiratory management of patients with severe COVID-19.
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